Optimizing urine albumin-to-creatinine ratio testing and referral pathways for chronic kidney disease: a nominal group technique consensus study among Italian experts.

Background: Chronic kidney disease (CKD) represents a major global health burden, often diagnosed at advanced stages when treatment is less effective. Albuminuria, assessed by the urine albumin-to-creatinine ratio (uACR), is a key biomarker for CKD detection and risk stratification. Despite guideline recommendations, adherence to uACR testing remains low, limiting early diagnosis and timely referral.

Real-world safety comparison of liraglutide and semaglutide in weight management: Insights from European pharmacovigilance data.

Background: In recent years, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), as liraglutide and semaglutide, for weight management has significantly risen. Even if these medications are effective, some concerns remain about their safety profiles, particularly regarding long-term adverse events (AEs). This study provides an evaluation of the safety profiles of liraglutide and semaglutide in a real-world setting.

Association of semaglutide with less limb events in people with type 2 diabetes and peripheral artery disease or foot ulcers: An observational study comparing matched cohorts.

Aims: To compare major limb events in individuals with type 2 diabetes who initiated either injective or oral semaglutide versus other glucose-lowering therapies (GLT) in a real-world setting.

Materials And Methods: This was a single-centre retrospective observational study on new users of diabetes medications. Participants had to have type 2 diabetes and a diagnosis of peripheral artery disease (PAD) or foot ulcers.

Digital Health in Diabetes Care: A Narrative Review from Monitoring to the Management of Systemic and Neurologic Complications.

: Despite the recent advances in glucose-lowering therapy, achieving diabetes control remains challenging. With the advancing progress of innovative digital health technologies, management of diabetes is taking advantage from telehealth and telemedicine, which allow for remote assistance, virtual visits, and monitoring of diabetes-related parameters, and facilitate the exchange of documents and reports to support clinical decisions. We aim to provide an overview of the impact of telehealth and digital technologies on the care of people with diabetes, from therapeutic management to the assessment of complications.

Patient-specific factors, patient preference, and nodule size as implications in the initial surgery of high risk indeterminate thyroid nodules.

Purpose: To evaluate the frequency of total thyroidectomy (TT) for thyroid nodules cytologically classified as high-risk indeterminate (TIR3B) and to explore the impact of patient specific factors (PSFs) (some clinical variables) associated with TT for follicular thyroid carcinoma (FTC). Moreover, we aim to investigate the nodule size as a factor influencing the risk of malignancy (ROM) and the risk of aggressiveness of FTC.

Methods: We retrieved consecutive FTC cases, and an equal number of follicular adenoma (FA) from adult patients with TIR3B thyroid nodules, which were operated in our Academic referral center between March 1, 2018, and December 31, 2024.

Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18-month follow-up of a randomized clinical trial.

Aims: In a six-month randomized clinical trial, improved peripheral perfusion has been shown with liraglutide, associated with favourable vascular effects in people with type 2 diabetes and peripheral artery disease (PAD). We aimed to evaluate the durability of these benefits and to elucidate some mechanisms underlying liraglutide's effect over an 18-month follow-up.

Methods: STARDUST was a randomized clinical trial which compared liraglutide up to 1.

Prevalence and Management of Complications of Laser Ablation for Benign Thyroid Nodules.

Context: Percutaneous laser ablation (LA) is today regarded as a valuable therapy for symptomatic, benign solid (noncystic) thyroid nodules (STNs).

Objective: We assessed the prevalence of complications from LA for benign and STNs and their management.

Methods: We conducted a systematic review with meta-analysis of data from published studies on LA of STNs, in addition to author institutions.

Sexual dysfunctions in inflammatory bowel disease: role of Mediterranean diet and quality of life.

Background: Dietary factors and chronic gastrointestinal diseases are frequent determinants of sexual dysfunctions (SD). Whether inflammatory bowel diseases (IBD) are associated with SD is not well known as well as the role of diet and quality of life (QoL).

Objectives: To evaluate the prevalence of SD in a cohort of IBD patients and assess the role of clinical-demographic variables, adherence to Mediterranean diet (MD) and QoL.

Short-term glucose variability as a determinant of the healing rate of diabetic foot ulcer: A retrospective study.

Background: The aim of this study was to describe the clinical characteristics of people with diabetic foot ulcer (DFU) according to glucose variability (GV) and to investigate the relationship between GV and DFU outcome in a population with type 2 diabetes (T2D) and DFU.

Methods: This is a retrospective study of 300 individuals aged 64.3 years (181 males) treated for DFU in a tertiary-care center with a regular follow-up for 6 months.

Liraglutide for Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease: The STARDUST Randomized Clinical Trial.

Importance: Peripheral artery disease (PAD) in diabetes may lead to diabetic foot ulcer and lower-extremities amputation. Glucagon-like peptide 1 receptor agonists have proven cardiovascular benefits in trials of people with type 2 diabetes at high cardiovascular risk.

Objective: To examine the effect of liraglutide on peripheral perfusion measured as peripheral transcutaneous oxygen pressure (TcPo2) in individuals with type 2 diabetes and PAD.

Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes clinical practice.

Aim: To assess and compare the metabolic and vascular effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT-2i) and dipeptidyl peptidase-4 inhibitors (DPP-4i) in the clinical practice of patients with type 2 diabetes in Italy.

Materials And Methods: GIOIA is a 2-year prospective, multicentre, quasi-experimental study that enrolled patients with type 2 diabetes initiating SGLT-2i or DPP-4i for inadequate glycaemic control [glycated haemoglobin (HbA1c) >7%] between March 2018 and March 2021. The primary endpoints were changes in markers of organ damage [carotid intima-media thickness (CIMT), albuminuria, myocardial function] and HbA1c from baseline to year 2.

Glucose control during breakthrough SARS-CoV-2 infections in vaccinated patients with type 1 diabetes.

Aims: This study aims at evaluating the trend of glycemic control metrics during the infection of SARS-CoV-2 in individuals with Type 1 Diabetes (T1D) using a Continuous Glucose Monitoring (CGM) system and vaccinated against COVID-19.

Materials And Methods: This is a retrospective study of T1D subjects who got a breakthrough SARS-CoV-2 infection between November 2021 and February 2022. Data of glycemic control of CGM-derived metrics were compared 14 days before COVID-19 (Time 1), 14 days during COVID-19 (Time 2) and 14 days after COVID-19 (Time 3).

BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes.

Purpose: To assess the magnitude and durability of the metabolic benefits by simplification of complex insulin treatments in patients with type 2 diabetes inadequately controlled by a full basal-bolus insulin regimen. Herein we report the results of the scheduled 2-year extension of the BEYOND trial.

Methods: Originally, 305 participants with inadequate glycemic control (HbA1c > 7.

An updated algorithm for an effective choice of continuous glucose monitoring for people with insulin-treated diabetes.

Purpose: Continuous Glucose Monitoring (CGM) is a key tool for insulin-treated people with diabetes (PwD). CGM devices include both real-time CGM (rtCGM) and intermittently scanned CGM (isCGM), which are associated with an improvement of glucose control and less hypoglycemia in clinical trials of people with type 1 and type 2 diabetes.

Methods: This is an expert position to update a previous algorithm on the most suitable choice of CGM for insulin-treated PwD in light of the recent evidence and clinical practice.